# A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Source: https://onco.cc/trials/nct06828991/  
OnCo record `nct06828991` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mosunetuzumab and clonoSEQ in Diffuse large B-cell lymphoma, run by Danielle Wallace, now recruiting.

## Summary

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP is a phase 2 interventional study registered as NCT06828991 by Danielle Wallace, with 40 participants planned, started 2025-09-04 and due to reach its primary completion in 2029-04-01. Interventions recorded: Mosunetuzumab, ClonoSEQ. Conditions recorded: Diffuse Large B-Cell Lymphoma (DLBCL).

Linked to the drug clonoSEQ because the registry names it among its interventions and Diffuse large B-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06828991
- Phase: 2
- Setting: ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL
- Sponsor: Danielle Wallace
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06828991: https://clinicaltrials.gov/study/NCT06828991

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [clonoSEQ](https://onco.cc/drugs/clonoseq/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06828991.json